Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment for advanced neuroendocrine tumors (NETs).
However, persistent thrombocytopenia (PT) has been reported and may compromise further therapies and outcomes.
This study aimed to identify predictive factors for PT defined as a platelet count <100 x 10
